Tempus AI, Inc. Class A Common Stock TEM

Tempus AI, Inc. es una empresa de tecnología. La empresa ofrece diagnósticos de próxima generación en múltiples áreas de enfermedades, con capacidades tecnológicas que aprovechan los datos y análisis para ayudar a personalizar la medicina. Las líneas de productos de la empresa incluyen genómica, datos y aplicaciones de inteligencia artificial (IA). Su línea de productos de genómica aprovecha sus laboratorios para proporcionar secuenciación de próxima generación, diagnósticos, reacción en cadena de la polimerasa (PCR), perfilado, genotipado molecular y otras pruebas de anatomía y patología molecular. Las aplicaciones de IA de la empresa se centran en el desarrollo y suministro de diagnósticos de naturaleza algorítmica, implementando nuevo software como un dispositivo médico, y construyendo y desplegando herramientas de apoyo a la toma de decisiones clínicas. Su producto principal de aplicaciones de IA es Next, una plataforma de IA que aprovecha el aprendizaje automático para aplicar una capa inteligente a los datos generados rutinariamente para identificar y minimizar proactivamente las brechas en la atención de pacientes de oncología y cardiología.

• GlobeNewswire Inc. 25 sept

  AI in Clinical Trials Market Set for Transformative Growth Through 2040, Unlocking Opportunities Across Trial Phases, Therapeutic Areas, End Users and Key Global Regions

  The global AI in clinical trials market is projected to expand from USD 2.09 billion in 2026 to USD 18.62 billion by 2040, growing at a 17.0% CAGR. AI applications including patient recruitment, predictive analytics, digital twins, and automation are addressing key challenges in drug development timelines and trial efficiency. Oncology represents the largest therapeutic area, while Asia-Pacific shows significant growth potential. Key players include IQVIA, Medidata, Dassault Systemes, and emerging AI companies like Deep 6 AI and AiCure.

  

• Zacks Investment Research 18 sept

  Zacks Investment Ideas feature highlights: NVIDIA, Advanced Micro Devices, Tempus, Moderna, Super Micro Computer and Aya Gold & Silver

  Despite 2026 being marked by macroeconomic headwinds, geopolitical pressures, and AI safety concerns, the S&P 500 remains just 2% off all-time highs. The article argues that price action speaks louder than negative headlines, and with retail investor sentiment at multi-year lows while stocks near record levels, historical patterns suggest a strong rally into year-end. Several stocks broke out on Thursday including AMD, Tempus AI, Moderna, Super Micro Computer, and Aya Gold & Silver.

  

• Zacks Investment Research 2 sept

  Why Is Inspire (INSP) Down 4.1% Since Last Earnings Report?

  Inspire Medical Systems (INSP) reported Q2 2026 earnings that beat estimates with adjusted EPS of 14 cents versus expected loss of 22 cents, and raised full-year 2026 guidance. However, U.S. revenues declined 9.6% year-over-year due to coding and reimbursement challenges, partially offset by strong 33.6% international revenue growth. The stock has declined 4.1% since earnings despite the Zacks Rank #1 (Strong Buy) rating.

  

• GlobeNewswire Inc. 25 ago

  AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

  Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

  

• The Motley Fool 23 ago

  Why Tempus AI Skyrocketed This Week

  Tempus AI stock surged 39.5% this week following positive Phase 3 trial results from Merck and Moderna for a jointly developed mRNA cancer vaccine combined with Keytruda immunotherapy. The gains were driven by Tempus's pending acquisition of Personalis, which developed the genomic tumor-profiling technology central to the vaccine's development. Despite the rally, Tempus remains down roughly 10% over the past year.